



TEL : 0091- 217 - 2310824
: 0091- 217 - 2451500
FAX : 0091- 217 - 2451521
E-MAIL : info@balajiamines.com
WEBSITE : http://www.balajiamines.com

Balaji



ISO 45001:2018
ISO 14001:2015
ISO 9001:2015
www.tuv.com
ID 9105038797



CIN : L24132MH1988PLC049387

AMINES LIMITED

... A Speciality Chemical Company

Regd. Off. : 'Balaji Towers' No. 9/1A/1,
Hotgi Road, Aasara Chowk, Solapur - 413 224.
Maharashtra. (India)

2nd August, 2025

To,
The General Manager-Department of
Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

The Manager-Listing Department,
National Stock Exchange of India Limited,
"Exchange Plaza", 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051.

Scrip Code : 530999

Symbol : BALAMINES

Dear Sir/Madam,

Sub.: Press Release in connection with Un-audited Financial Results for the Quarter ended 30th June, 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please enclosed herewith a copy of Press Release in connection with the Un-audited Financial Results for the Quarter ended 30th June, 2025.

The aforesaid information is also being made available on the website of the Company at <https://www.balajiamines.com/investor-relations.php>.

This is for your information and records.

Thanking you.

Yours faithfully,

For Balaji Amines Limited

Abhijeet Kothadiya
Company Secretary & Compliance Officer

Encl.: a/a

Consolidated Q1FY26 Revenue stood at ₹ 367 Crore;**EBITDA stood at ₹ 64 Crore;****Net Profit stood at ₹ 31 Crore**

Solapur, August 02, 2025: Balaji Amines Limited (“Company”), a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines, Ethyl Amines, Derivatives of Amines and other Specialty Chemicals, announced its unaudited financial results for the quarter ended June 30th, 2025.

Key Financial Highlights are as follows :

Particulars (₹ Cr.)	Standalone		Consolidated	
	Q1 FY26	Q4 FY25	Q1 FY26	Q4 FY25
Total Income (Rs. Cr)	327	327	367	361
EBITDA (Rs. Cr)	64	64	64	68
EBITDA Margin (%)	20%	20%	17%	19%
PAT (Rs. Cr)	40	40	37	40
PAT Margin (%)	12%	12%	10%	11%
Cash PAT* (Rs. Cr)	53	51	51	43
Cash PAT Margin (%)	16%	16%	14%	12%
Sales Volume (in MT)	24,847	24,047	27,570	25,871

*Cash PAT is PAT + Depreciation + Deferred tax

Particulars (₹ Cr.)	Standalone		Consolidated	
	Q1 FY26	Q1 FY25	Q1 FY26	Q1 FY25
Total Income (Rs. Cr)	327	338	367	393
EBITDA (Rs. Cr)	64	64	64	74
EBITDA Margin (%)	20%	19%	17%	19%
PAT (Rs. Cr)	40	41	37	46
PAT Margin (%)	12%	12%	10%	12%
Cash PAT* (Rs. Cr)	53	52	51	59
Cash PAT Margin (%)	16%	15%	12%	15%
Sales Volume (in MT)	24,847	25,551	27,570	28,071

*Cash PAT is PAT + Depreciation + Deferred tax

Consolidated Performance Highlights for Q1FY26

Revenue from Operations for Q1FY26 stood at ₹ 367 crore, as compared to ₹ 361 crore in Q4FY25 keeping the performance track intact though the volume growth is seen. The stable commodity prices have allowed us to have the track of performance.

Total volumes stood at 27,570 MT for Q1FY26 as against 25,871 MT in Q4FY25.

For Q1FY26,

- Amines volumes stood at 7,573 MT
- Amines Derivatives volumes stood at 8,108 MT
- Specialty Chemicals volumes stood at 11,889 MT

EBITDA for Q1FY26 was ₹ 64 crore, as compared to ₹ 68 crore in Q4FY25 and ₹ 74 crore in Q1FY25.

EBITDA margin for Q1FY26 stood at 17% as against 19% in Q4FY25 and 19% in Q1FY25.

PAT for Q1FY26 was ₹ 37 crore as compared to ₹ 40 crore in Q4FY25. **Diluted EPS** for Q1FY26 stood at ₹ 11.73 per equity share as against ₹ 12.36 in Q4FY25.

On a standalone basis, we are a zero-debt company.

Update on New Projects Commissioned and New Proposed Products/Projects

- **Dimethyl Ether (DME)** : The project for manufacture of DME is under execution at Unit-IV. The Plant is expected to be commissioned during the FY 2025-26. This has an application in the Aerosol industry apart from using it as a replacement to LPG for Industrial and Commercial usage.
- **N-Methyl Morpholine (NMM)** : - 5000 TPA is under execution and expected to be commissioned during the FY 2025-26.
- **Acetonitrile** : Improved process based ACN plant is under execution, the same is expected to be commissioned during the FY 2026-27.

All the above projects would be completed as planned with the internal accruals.

New expansion of Rs. 750 crs in Subsidiary Balaji Speciality Chemicals Limited

Investment is being made for wide range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30%(Solution), Sodium Cyanide (NaCN) 100%(Solid), Ethylene Diamine Tetra Acetic Acid (EDTA), Ethylene Diamine Tetra Acetic Acid Disodium Salt(EDTA-2Na),

Notably, the Industries, Energy, and Labour Department, Government of Maharashtra, has granted Mega Project status to our Expansion Project for Balaji Speciality Chemicals under the Packaged Scheme of Incentives (PSI), 2019, with a proposed investment of Rs. 750 Crores in a phased manner.

The Unit- 1 Brown field project for EDA based products is progressing as per the plan, the plant will be commissioned during the Q1 of FY 2026-27.

The Unit - 2 Greenfield Project for setting up of HCN, NaCN, EDTA plants at MIDC Chincholi are progressing as per the plan and most of the critical equipment are already at site and installation works are going on at brisk pace. As planned the plants will be commissioned during the next FY 2026-27.

On the performance, Mr. D. Ram Reddy, Managing Director, commented, “During Q1 FY26, our financial and business performance remained stable, supported by a disciplined working model with stable commodity prices. As volume uptake gradually improves, we anticipate EBITDA and PAT margins to expand, in line with the industry recovery. With the present global and domestic scenario, the utilization of expanded capacities may be impacted in the coming quarters until the basic contribution for our products come through.

At BAL, we remain focused on driving sustainable progress, backed by ongoing investments in key projects and our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade are yet to yield better volumes in serving the domestic market as we have a better product to offer at a competitive pricing, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers.

Looking ahead, we maintain a stable outlook for short term opportunities, anticipating growth and increased market driven balanced approach for medium to long term with better prospects. As our inherent strengths and competencies position us as a leading force in Amines and Specialty Chemicals, helping us navigate market dynamics and advance towards greater excellence.”

About Balaji Amines Limited (BAL)

Balaji Amines Ltd (BAL), set up in 1988, is a leading manufacturer of Aliphatic Amines in India. Broadly, the company is specialised in manufacturing Methyl Amines, Ethyl Amines, Derivatives of Aliphatic Amines and Specialty Chemicals. Its business is broadly classified into three segments - Amines, Specialty Chemicals and Derivatives. BAL commenced manufacturing of Methyl Amines in 1990, and later added facilities of Ethyl Amines and other derivatives of Methyl amines and Ethyl amines. The company enjoys leadership position in many of its products like Monomethylamine (MMA), Dimethyl amine (DMA), Trimethylamine (TMA), Dimethyl Amino Ethanol (DMAE), Mono Methyl Amino Ethanol etc.

It caters to a host of industries like Pharma, Agro Chemicals, Paint Stripping & Resins, Rubber cleaning chemicals etc. The company has four state of the art manufacturing facilities – three near Solapur and one near Hyderabad. In addition, BAL possesses a fully furnished Laboratory which helps the company in development of newer products. A majority of its products are being exported to major customers worldwide and the company has become one of the leaders in Specialty Chemicals among the International Specialty Chemical players. The company also operates a 5-star hotel in Solapur – Balaji Sarovar. It has tied up with Sarovar group for management of this hotel.

For more information, please visit www.balajiamines.com

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Company	Investor Relations Advisors
 Balaji Amines Limited CIN No: L24132MH1988PLC049387 Email id: cs@balajiamines.com	 MUFG Intime India Private Limited Mr. Bhavya Shah : +91 80827 48577 bhavya.shah@in.mpms.mufg.com Mr. Chirag Bhatiya : +91 8104778836 chirag.bhatiya@in.mpms.mufg.com